ARCT Arcturus Therapeutics Holdings Inc
Price (delayed)
$14.55
Market cap
$394.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3
Enterprise value
$127.56M
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™
Highlights
Arcturus Therapeutics Holdings's debt has decreased by 3.8% QoQ and by 3.5% YoY
The net income has dropped by 172% year-on-year and by 29% since the previous quarter
The company's EPS has shrunk by 168% YoY and by 28% QoQ
Key stats
What are the main financial stats of ARCT
Market
Valuations
Earnings
Shares outstanding
27.12M
Market cap
$394.59M
Enterprise value
$127.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.64
Price to sales (P/S)
2.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.84
Revenue
$152.31M
Gross profit
$152.31M
Operating income
-$95.67M
Net income
-$80.94M
EBIT
-$96.14M
EBITDA
-$92.6M
Free cash flow
-$60.4M
Per share
Balance sheet
Liquidity
EPS
-$3
EPS diluted
-$3
Free cash flow per share
-$2.24
Book value per share
$8.9
Revenue per share
$5.64
TBVPS
$12.74
Total assets
$344.07M
Total liabilities
$103.09M
Debt
$25M
Equity
$240.98M
Working capital
$240.49M
Debt to equity
0.1
Current ratio
4.67
Quick ratio
4.52
Net debt/EBITDA
2.88
Margins
Efficiency
Dividend
EBITDA margin
-60.8%
Gross margin
100%
Net margin
-53.1%
Operating margin
-62.8%
Return on assets
-21.3%
Return on equity
-31.6%
Return on invested capital
-899.5%
Return on capital employed
-34.5%
Return on sales
-63.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARCT stock price
How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-8.89%
1 week
-13.34%
1 month
-10.13%
1 year
-60.88%
YTD
-14.26%
QTD
-14.26%
Financial performance
How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$152.31M
Gross profit
$152.31M
Operating income
-$95.67M
Net income
-$80.94M
Gross margin
100%
Net margin
-53.1%
Arcturus Therapeutics Holdings's net margin has shrunk by 198% YoY and by 36% QoQ
The net income has dropped by 172% year-on-year and by 29% since the previous quarter
Arcturus Therapeutics Holdings's operating margin has decreased by 34% YoY and by 25% QoQ
Arcturus Therapeutics Holdings's operating income has decreased by 22% YoY and by 19% QoQ
Growth
What is Arcturus Therapeutics Holdings's growth rate over time
Valuation
What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.64
P/S
2.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.84
The company's EPS has shrunk by 168% YoY and by 28% QoQ
ARCT's P/B is 56% lower than its 5-year quarterly average of 3.7 and 37% lower than its last 4 quarters average of 2.6
ARCT's equity is down by 13% year-on-year and by 8% since the previous quarter
ARCT's price to sales (P/S) is 94% lower than its 5-year quarterly average of 40.9 and 44% lower than its last 4 quarters average of 4.6
The revenue has declined by 9% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Arcturus Therapeutics Holdings business performance
The company's return on sales has shrunk by 136% YoY and by 28% QoQ
Arcturus Therapeutics Holdings's ROIC has plunged by 64% from the previous quarter
The ROA has decreased by 37% QoQ
The company's return on equity fell by 34% QoQ
Dividends
What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARCT.
Financial health
How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total liabilities has decreased by 32% YoY and by 5% QoQ
Arcturus Therapeutics Holdings's total assets has decreased by 20% YoY and by 7% QoQ
Arcturus Therapeutics Holdings's debt is 90% lower than its equity
ARCT's equity is down by 13% year-on-year and by 8% since the previous quarter
The debt to equity has increased by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.